Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
FHCC
MCID: FBR086
MIFTS: 55

Fibrolamellar Carcinoma (FHCC)

Categories: Cancer diseases, Endocrine diseases, Gastrointestinal diseases, Liver diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Fibrolamellar Carcinoma

About this section

MalaCards integrated aliases for Fibrolamellar Carcinoma:

Name: Fibrolamellar Carcinoma 12 53 15
Fibrolamellar Hepatocellular Carcinoma 12 53 59 44 73
Eosinophilic Hepatocellular Carcinoma with Lamellar Fibrosis 53
Polygonal Cell Hepatocellular Carcinoma with Fibrous Stroma 53
Hepatocellular Carcinoma with Increased Stromal Fibrosis 53
Hepatocellular Carcinoma, Fibrolamellar 12
Eosinophilic Glassy Cell Hepatoma 53
Fibrolamellar Oncocytic Hepatoma 53
Oncocytic Hepatocellular Tumor 12
Fibrolamellar Hepatocarcinoma 59
Fl-Hcc 53
Fhcc 59

Characteristics:

Orphanet epidemiological data:

59
fibrolamellar hepatocellular carcinoma
Inheritance: Not applicable; Prevalence: <1/1000000 (United States); Age of onset: Adolescent,Adult;

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Liver diseases Endocrine diseases Gastrointestinal diseases
See all MalaCards categories (disease lists)
ICD10: 34
Orphanet: 59  
Rare hepatic diseases


External Ids:

Disease Ontology 12 DOID:5015
MeSH 44 C537258
NCIt 50 C4131
SNOMED-CT 68 15619004
Orphanet 59 ORPHA401920
UMLS via Orphanet 74 C0334287
ICD10 via Orphanet 34 C22.0
UMLS 73 C0334287
Sources

Summaries for Fibrolamellar Carcinoma

About this section
NIH Rare Diseases : 53 Fibrolamellar carcinoma (FLC) is a rare form of liver cancer which is generally diagnosed in adolescents and young adults (before age 40). Many people with early FLC have no signs or symptoms of the condition. When present, symptoms are often nonspecific (i.e. abdominal pain, weight loss, malaise) and blamed on other, more common conditions. The exact underlying cause of FLC is poorly understood. Unlike other forms of liver cancer, FLC typically occurs in the absence of underlying liver inflammation or scarring; thus, specific risk factors for this condition remain unidentified. FLC is typically treated with surgical resection.

MalaCards based summary : Fibrolamellar Carcinoma, also known as fibrolamellar hepatocellular carcinoma, is related to mixed fibrolamellar hepatocellular carcinoma and hepatocellular carcinoma, and has symptoms including fever, abdominal pain and icterus. An important gene associated with Fibrolamellar Carcinoma is PRKACA (Protein Kinase CAMP-Activated Catalytic Subunit Alpha), and among its related pathways/superpathways are ERK Signaling and Developmental Biology. The drugs Paclitaxel and Polyestradiol phosphate have been mentioned in the context of this disorder. Affiliated tissues include liver, lung and ovary, and related phenotypes are Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance and cardiovascular system

Disease Ontology : 12 A hepatocellular carcinoma characterized microscopically by laminated fibrous layers interspersed between the tumour cells. The polygonal, deeply eosinophilic tumor cells arise in non-cirrhotic livers.

Wikipedia : 76 Fibrolamellar hepatocellular carcinoma (FHCC) is a rare form of hepatocellular carcinoma (HCC) that... more...

Sources

Related Diseases for Fibrolamellar Carcinoma

About this section

Diseases related to Fibrolamellar Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 99)
# Related Disease Score Top Affiliating Genes
1 mixed fibrolamellar hepatocellular carcinoma 32.1 DNAJB1 PRKACA
2 hepatocellular carcinoma 10.4
3 obstructive jaundice 10.3
4 encephalopathy 10.3
5 ovary neuroendocrine neoplasm 10.3 KRT7 SYP
6 mucinous adenofibroma 10.3 KRT7 SYP
7 small cell carcinoma of the bladder 10.3 KRT7 SYP
8 sensory organ benign neoplasm 10.2 KRT7 SYP
9 middle ear adenoma 10.2 KRT7 SYP
10 pancreatic serous cystadenoma 10.2 KRT7 SYP
11 seminal vesicle tumor 10.2 KRT7 SYP
12 glycogen-rich clear cell breast carcinoma 10.2 KRT7 SYP
13 pulmonary sclerosing hemangioma 10.2 KRT7 SYP
14 sclerosing hemangioma 10.2 KRT7 SYP
15 mucinous ovarian cystadenoma 10.2 KRT7 SYP
16 budd-chiari syndrome 10.2
17 gastric squamous cell carcinoma 10.2 KRT7 SYP
18 plagiocephaly 10.2 FGFR1 FGFR2
19 osteoglophonic dysplasia 10.2 FGFR1 FGFR2
20 rosette-forming glioneuronal tumor 10.2 FGFR1 SYP
21 ovarian mucinous neoplasm 10.2 KRT7 SYP
22 thymus lipoma 10.2 KRT7 SYP
23 parachordoma 10.2 KRT7 VIM
24 atypical choroid plexus papilloma 10.2 KRT7 SYP
25 secretory meningioma 10.2 KRT7 VIM
26 adenoid squamous cell carcinoma 10.2 KRT7 VIM
27 primary hepatic neuroendocrine carcinoma 10.2 SYP VIM
28 nodular hidradenoma 10.2 KRT7 VIM
29 hidradenoma 10.2 KRT7 VIM
30 papillary tumor of the pineal region 10.2 SYP VIM
31 papillary adenoma 10.2 KRT7 VIM
32 benign metastasizing leiomyoma 10.2 KRT7 VIM
33 jackson-weiss syndrome 10.2 FGFR1 FGFR2
34 bile duct adenoma 10.2 KRT7 VIM
35 chordoid meningioma 10.2 SYP VIM
36 cholangiocarcinoma 10.2
37 monophasic synovial sarcoma 10.2 KRT7 VIM
38 spiradenoma 10.2 KRT7 VIM
39 clear cell ependymoma 10.2 SYP VIM
40 immune system organ benign neoplasm 10.2 KRT7 SYP
41 astroblastoma 10.2 SYP VIM
42 melanotic neuroectodermal tumor 10.2 SYP VIM
43 metanephric adenoma 10.2 KRT7 VIM
44 angiocentric glioma 10.2 SYP VIM
45 adenomatoid tumor 10.2 KRT7 VIM
46 cystic teratoma 10.2 KRT7 SYP
47 radioulnar synostosis 10.2 FGFR1 FGFR2
48 basaloid squamous cell carcinoma 10.2 KRT7 SYP
49 desmoplastic small round cell tumor 10.2 SYP VIM
50 perivascular epithelioid cell tumor 10.2 SYP VIM

Graphical network of the top 20 diseases related to Fibrolamellar Carcinoma:



Diseases related to Fibrolamellar Carcinoma
Sources

Symptoms & Phenotypes for Fibrolamellar Carcinoma

About this section

UMLS symptoms related to Fibrolamellar Carcinoma:


fever, abdominal pain, icterus, malaise

GenomeRNAi Phenotypes related to Fibrolamellar Carcinoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 8.92 FGFR2 ITGAV ITGB4 VIM

MGI Mouse Phenotypes related to Fibrolamellar Carcinoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.92 CCKBR FGFR1 FGFR2 ITGA1 ITGAV ITGB4
2 homeostasis/metabolism MP:0005376 9.85 CCKBR FGFR1 FGFR2 ITGA1 ITGAV ITGB4
3 digestive/alimentary MP:0005381 9.73 CCKBR FGFR1 FGFR2 ITGAV ITGB4 NR0B2
4 nervous system MP:0003631 9.56 CCKBR FGFR1 FGFR2 ITGAV ITGB4 PRKACA
5 renal/urinary system MP:0005367 9.23 CCKBR FGFR1 FGFR2 ITGA1 ITGAV ITGB4
Sources

Drugs & Therapeutics for Fibrolamellar Carcinoma

About this section

Drugs for Fibrolamellar Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 39)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
2
Polyestradiol phosphate Approved Phase 2 28014-46-2
3 Estradiol valerate Approved, Investigational, Vet_approved Phase 2 979-32-8
4
Fulvestrant Approved, Investigational Phase 2 129453-61-8 17756771 104741
5
Trastuzumab Approved, Investigational Phase 2 180288-69-1 9903
6
Estradiol Approved, Investigational, Vet_approved Phase 2 50-28-2 5757
7
Leuprolide Approved, Investigational Phase 2 53714-56-0 657181 3911
8
Sirolimus Approved, Investigational Phase 2 53123-88-9 46835353 6436030 5284616
9
Letrozole Approved, Investigational Phase 2 112809-51-5 3902
10
Everolimus Approved Phase 2 159351-69-6 6442177
11
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
12
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
13 Cola Phase 2
14 Antineoplastic Agents, Hormonal Phase 2
15 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2
16 Mitogens Phase 2,Phase 1
17 Antineoplastic Agents, Phytogenic Phase 2
18 Estrogens Phase 2
19 Antimitotic Agents Phase 2
20 Albumin-Bound Paclitaxel Phase 2
21 Hormone Antagonists Phase 2
22 Estradiol 17 beta-cypionate Phase 2
23 Hormones Phase 2
24 Estrogen Receptor Antagonists Phase 2
25 Estradiol 3-benzoate Phase 2
26 Estrogen Antagonists Phase 2
27 Immunologic Factors Phase 2
28 Aromatase Inhibitors Phase 2
29 Steroid Synthesis Inhibitors Phase 2
30 Antibiotics, Antitubercular Phase 2
31 Anti-Bacterial Agents Phase 2
32 Immunosuppressive Agents Phase 2
33 Antifungal Agents Phase 2
34 Fertility Agents Phase 2
35 Anti-Infective Agents Phase 2
36 Angiogenesis Inhibitors Phase 2
37 Angiogenesis Modulating Agents Phase 2
38 Liver Extracts Phase 2
39 Endothelial Growth Factors Phase 1

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 A Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar Carcinoma Completed NCT02234986 Phase 2 ENMD-2076
2 Neratinib HER Mutation Basket Study (SUMMIT) Recruiting NCT01953926 Phase 2 Neratinib;Paclitaxel;Fulvestrant;Trastuzumab
3 Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) With Leuprolide + Letrozole and (3) Everolimus + EDT in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLL-HCC) Active, not recruiting NCT01642186 Phase 2 everolimus;letrozole plus leuprolide;combination of everolimus, letrozole and leuprolide
4 Study of Sunitinib in Patients With Advanced/Inoperable Fibrolamellar Carcinoma Terminated NCT01215565 Phase 2 Sutent
5 Sequential, Related Donor Partial Liver Transplantation Followed by Bone Marrow Transplantation for Hepatocellular Carcinoma (HCC) Withdrawn NCT02702960 Phase 2 Cyclophosphamide;Mesna;Filgrastim;Tacrolimus;mycophenolate mofetil;Prednisone;Antithymocyte globulin;fludarabine
6 Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery Recruiting NCT02159989 Phase 1 Sapanisertib
7 Natural History Study of Children and Adults With Fibrolamellar Hepatocellular Carcinoma Not yet recruiting NCT03748927
8 Biomarkers in Stored Tumor Samples From Younger Patients With Liver Cancer Withdrawn NCT00899002

Search NIH Clinical Center for Fibrolamellar Carcinoma

Cochrane evidence based reviews: fibrolamellar hepatocellular carcinoma

Sources

Genetic Tests for Fibrolamellar Carcinoma

About this section
Sources

Anatomical Context for Fibrolamellar Carcinoma

About this section

MalaCards organs/tissues related to Fibrolamellar Carcinoma:

41
Liver, Lung, Ovary, Kidney, Bone, Breast, Thymus
Sources

Publications for Fibrolamellar Carcinoma

About this section

Articles related to Fibrolamellar Carcinoma:

(show top 50) (show all 268)
# Title Authors Year
1
Fibrolamellar Carcinoma: Recent Advances and Unresolved Questions on the Molecular Mechanisms. ( 29471565 )
2018
2
Favorable response to mammalian target of rapamycin inhibition in a young patient with unresectable fibrolamellar carcinoma of the liver. ( 29473972 )
2018
3
Fibrolamellar Carcinoma: What Is New and Why It Matters. ( 29751881 )
2018
4
Fibrolamellar Carcinoma: A Concise Review. ( 30141990 )
2018
5
Management of fibrolamellar hepatocellular carcinoma. ( 30395718 )
2018
6
TP53 germline and somatic mutations in a patient with fibrolamellar hepatocellular carcinoma. ( 28477317 )
2018
7
Intracranial metastasis in fibrolamellar hepatocellular carcinoma. ( 29286561 )
2018
8
Conformational Landscape of the PRKACA-DNAJB1 Chimeric Kinase, the Driver for Fibrolamellar Hepatocellular Carcinoma. ( 29335433 )
2018
9
Fibrolamellar Hepatocellular Carcinoma: Treatment with Yttrium-90 and Subsequent Surgical Resection. ( 29468286 )
2018
10
Imaging features of fibrolamellar hepatocellular carcinoma in gadoxetic acid-enhanced MRI. ( 29490696 )
2018
11
Hardened Liver Due to Fibrolamellar Hepatocellular Carcinoma. ( 29505903 )
2018
12
Curative lung metastectomy and complete pathological response after neo-adjuvant GEMOX chemotherapy for relapse fibrolamellar hepatocellular carcinoma. ( 29531203 )
2018
13
Non coding RNA analysis in fibrolamellar hepatocellular carcinoma. ( 29535801 )
2018
14
Living-Donor Liver Transplant for Fibrolamellar Hepatocellular Carcinoma With Hilar Lymph Node Metastasis: A Case Report. ( 29633928 )
2018
15
Utility of Cytokeratin7 Immunocytochemistry in the Cytopathological Diagnosis of Fibrolamellar Hepatocellular Carcinoma. ( 29643652 )
2018
16
Fibrolamellar hepatocellular carcinoma: multiphasic CT features of the primary tumor on pre-therapy CT and pattern of distant metastases. ( 29948061 )
2018
17
Liver clear cell foci and viral infection are associated with non-cirrhotic, non-fibrolamellar hepatocellular carcinoma in young patients from South America. ( 30061721 )
2018
18
Acquired ornithine transcarbamylase deficiency in pediatric and adolescent patients with fibrolamellar hepatocellular carcinoma. ( 30094907 )
2018
19
Fibrolamellar hepatocellular carcinoma with multiple lung metastases treated with multidisciplinary therapy. ( 30101933 )
2018
20
Fibrolamellar carcinoma: A histologically unique tumor with unique molecular findings. ( 28110996 )
2017
21
Comprehensive analysis of The Cancer Genome Atlas reveals a unique gene and non-coding RNA signature of fibrolamellar carcinoma. ( 28304380 )
2017
22
Fibrolamellar Carcinoma in the Carney Complex: PRKAR1A Loss Instead of the Classic DNAJB1-PRKACA Fusion. ( 29222914 )
2017
23
An unusual case of jaundice: Biliary tumor thrombus in fibrolamellar hepatocellular carcinoma. ( 28531870 )
2017
24
Genome and transcriptome profiling of fibrolamellar hepatocellular carcinoma demonstrates p53 and IGF2BP1 dysregulation. ( 28486549 )
2017
25
CD47 is not Over-Expressed in Fibrolamellar Hepatocellular Carcinoma. ( 28801364 )
2017
26
Environmental exposures as a risk factor for fibrolamellar carcinoma. ( 28256571 )
2017
27
Molecular testing for the clinical diagnosis of fibrolamellar carcinoma. ( 28862261 )
2017
28
Liver transplantation for fibrolamellar hepatocellular carcinoma: A national perspective. ( 27878821 )
2017
29
A Proposed Physiopathological Pathway to Hyperammonemic Encephalopathy in a Non-Cirrhotic Patient with Fibrolamellar Hepatocellular Carcinoma without Ornithine Transcarbamylase (OTC) Mutation. ( 28270654 )
2017
30
Clinicopathological features and surgical outcome of patients with fibrolamellar hepatocellular carcinoma (experience with 22 patients over a 15-year period). ( 28289511 )
2017
31
Fibrolamellar hepatocellular carcinoma with ovarian metastasis - an unusual presentation. ( 28523316 )
2017
32
CRISPR/Cas9 Engineering of Adult Mouse Liver Demonstrates That the Dnajb1-Prkaca Gene Fusion Is Sufficient to Induce Tumors Resembling Fibrolamellar Hepatocellular Carcinoma. ( 28923495 )
2017
33
Multi-organ Metastasis of Fibrolamellar Hepatocellular Carcinoma in a Malayan Gharial (Tomistoma schlegelii). ( 28942308 )
2017
34
DNAJB1-PRKACA fusion kinase interacts with β-catenin and the liver regenerative response to drive fibrolamellar hepatocellular carcinoma. ( 29162699 )
2017
35
Fibrolamellar hepatocellular carcinoma in ascitic fluid: A case report with cytohistological correlation. ( 27218242 )
2016
36
Duodenal Recurrence of Fibrolamellar Carcinoma 12 Years After Partial Hepatectomy and Adjuvant Chemotherapy. ( 27921059 )
2016
37
Fibrolamellar Hepatocellular Carcinoma: Mechanistic Distinction From Adult Hepatocellular Carcinoma. ( 26990031 )
2016
38
A genomic case study of mixed fibrolamellar hepatocellular carcinoma. ( 27029710 )
2016
39
Enhanced cAMP-stimulated protein kinase A activity in human fibrolamellar hepatocellular carcinoma. ( 27027723 )
2016
40
Contemporary management of fibrolamellar hepatocellular carcinoma: diagnosis, treatment, outcome, prognostic factors, and recent developments. ( 27215576 )
2016
41
Prognosis of Fibrolamellar Carcinoma Compared to Non-cirrhotic Conventional Hepatocellular Carcinoma. ( 27456016 )
2016
42
Hyperammonemic Encephalopathy Associated With Fibrolamellar Hepatocellular Carcinoma: Case Report, Literature Review, and Proposed Treatment Algorithm. ( 26975868 )
2016
43
Fibrolamellar hepatocellular carcinoma: a rare entity diagnosed by abdominal ultrasound. ( 27554381 )
2016
44
Successful Liver Transplantation for Hyperammonemic Fibrolamellar Hepatocellular Carcinoma. ( 27807568 )
2016
45
EDUCATION AND IMAGING. Hepatobiliary and Pancreatic: Post-transplant recurrence of fibrolamellar hepatocellular carcinoma in lung and pancreas. ( 26228303 )
2016
46
Fibrolamellar hepatocellular carcinoma presenting as obstructive jaundice: uncommon presentation of a rare entity. ( 25866594 )
2015
47
Prognostic factors in fibrolamellar hepatocellular carcinoma in young people. ( 25598114 )
2015
48
DNAJB1-PRKACA is specific for fibrolamellar carcinoma. ( 25698061 )
2015
49
Fibrolamellar carcinoma versus scirrhous hepatocellular carcinomaa88: diagnostic usefulness of CD68. ( 26712049 )
2015
50
Clinical and pathological evaluation of fibrolamellar hepatocellular carcinoma: a single center study of 21 cases. ( 26017653 )
2015
Sources

Variations for Fibrolamellar Carcinoma

About this section

Cosmic variations for Fibrolamellar Carcinoma:

9 (show top 50) (show all 3321)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM1626018 ZXDB liver,NS,carcinoma,hepatocellular carcinoma c.1308C>A p.D436E 23:57593356-57593356 27
2 COSM1615665 ZSWIM1 liver,NS,carcinoma,hepatocellular carcinoma c.1399A>C p.S467R 20:45883991-45883991 27
3 COSM1602238 ZSCAN20 liver,NS,carcinoma,hepatocellular carcinoma c.2314G>T p.G772W 1:33494658-33494658 27
4 COSM6951673 ZRSR2 liver,NS,carcinoma,hepatocellular carcinoma c.304G>T p.E102* 23:15803788-15803788 27
5 COSM1616325 ZNRF3 liver,NS,carcinoma,hepatocellular carcinoma c.859A>G p.M287V 22:29049340-29049340 27
6 COSM3707827 ZNFX1 liver,NS,carcinoma,hepatocellular carcinoma c.2580G>A p.L860L 20:49257501-49257501 27
7 COSM3707828 ZNFX1 liver,NS,carcinoma,hepatocellular carcinoma c.2580G>A p.L860L 20:49257501-49257501 27
8 COSM1623051 ZNF853 liver,NS,carcinoma,hepatocellular carcinoma c.1610G>T p.G537V 7:6622601-6622601 27
9 COSM1612127 ZNF829 liver,NS,carcinoma,hepatocellular carcinoma c.829T>A p.F277I 19:36891962-36891962 27
10 COSM1618451 ZNF827 liver,NS,carcinoma,hepatocellular carcinoma c.1741C>T p.L581L 4:145885684-145885684 27
11 COSM1611545 ZNF653 liver,NS,carcinoma,hepatocellular carcinoma c.1553A>C p.H518P 19:11485673-11485673 27
12 COSM1612685 ZNF615 liver,NS,carcinoma,hepatocellular carcinoma c.141G>A p.V47V 19:52002156-52002156 27
13 COSM1612018 ZNF536 liver,NS,carcinoma,hepatocellular carcinoma c.3900G>T p.K1300N 19:30557161-30557161 27
14 COSM1618219 ZNF518B liver,NS,carcinoma,hepatocellular carcinoma c.1624G>T p.E542* 4:10444705-10444705 27
15 COSM1624399 ZNF462 liver,NS,carcinoma,hepatocellular carcinoma c.6715G>T p.V2239L 9:106974156-106974156 27
16 COSM1609798 ZNF276 liver,NS,carcinoma,hepatocellular carcinoma c.1219C>G p.L407V 16:89734008-89734008 27
17 COSM1605856 ZNF26 liver,NS,carcinoma,hepatocellular carcinoma c.1010C>T p.T337I 12:133010889-133010889 27
18 COSM1602404 ZMYND12 liver,NS,carcinoma,hepatocellular carcinoma c.425-1G>T p.? 1:42440026-42440026 27
19 COSM1607880 ZFYVE26 liver,NS,carcinoma,hepatocellular carcinoma c.663C>A p.A221A 14:67807621-67807621 27
20 COSM3661787 ZFR liver,NS,carcinoma,hepatocellular carcinoma c.2882C>T p.P961L 5:32364229-32364229 27
21 COSM1270878 ZFP36L2 liver,NS,carcinoma,hepatocellular carcinoma c.910T>G p.S304A 2:43224894-43224894 27
22 COSM1612900 ZFP28 liver,NS,carcinoma,hepatocellular carcinoma c.1865G>A p.C622Y 19:56554650-56554650 27
23 COSM3663890 ZFHX4 liver,NS,carcinoma,hepatocellular carcinoma c.10601C>G p.S3534C 8:76864315-76864315 27
24 COSM6969923 ZFHX3 liver,NS,carcinoma,hepatocellular carcinoma c.10852C>A p.P3618T 16:72787424-72787424 27
25 COSM3717069 ZFHX3 liver,NS,carcinoma,hepatocellular carcinoma c.8342A>G p.Q2781R 16:72794340-72794340 27
26 COSM6219678 ZFHX3 liver,NS,carcinoma,hepatocellular carcinoma c.9997C>T p.Q3333* 16:72788279-72788279 27
27 COSM1613453 ZEB2 liver,NS,carcinoma,hepatocellular carcinoma c.1141A>G p.M381V 2:144400046-144400046 27
28 COSM3717124 ZCCHC14 liver,NS,carcinoma,hepatocellular carcinoma c.71A>T p.Q24L 16:87491757-87491757 27
29 COSM1608898 ZC3H7A liver,NS,carcinoma,hepatocellular carcinoma c.2866A>G p.N956D 16:11751367-11751367 27
30 COSM3705381 ZBTB41 liver,NS,carcinoma,hepatocellular carcinoma c.1700G>A p.R567K 1:197178489-197178489 27
31 COSM1601838 ZBTB40 liver,NS,carcinoma,hepatocellular carcinoma c.3339C>A p.F1113L 1:22524258-22524258 27
32 COSM1610770 ZBTB4 liver,NS,carcinoma,hepatocellular carcinoma c.454G>T p.G152C 17:7466348-7466348 27
33 COSM1601260 ZBTB37 liver,NS,carcinoma,hepatocellular carcinoma c.620G>C p.S207T 1:173870845-173870845 27
34 COSM1624206 ZBTB10 liver,NS,carcinoma,hepatocellular carcinoma c.2136A>G p.T712T 8:80518852-80518852 27
35 COSM1624207 ZBTB10 liver,NS,carcinoma,hepatocellular carcinoma c.2311A>G p.I771V 8:80519295-80519295 27
36 COSM1616586 ZBED4 liver,NS,carcinoma,hepatocellular carcinoma c.2225A>C p.E742A 22:49885887-49885887 27
37 COSM1624117 YTHDF3 liver,NS,carcinoma,hepatocellular carcinoma c.1568A>G p.N523S 8:63187582-63187582 27
38 COSM1603361 YME1L1 liver,NS,carcinoma,hepatocellular carcinoma c.2006A>G p.H669R 10:27116230-27116230 27
39 COSM1617254 YEATS2 liver,NS,carcinoma,hepatocellular carcinoma c.501C>T p.N167N 3:183722100-183722100 27
40 COSM3663693 XPO7 liver,NS,carcinoma,hepatocellular carcinoma c.806A>G p.Y269C 8:21977812-21977812 27
41 COSM1609152 XPO6 liver,NS,carcinoma,hepatocellular carcinoma c.882C>T p.G294G 16:28156289-28156289 27
42 COSM6957749 XPO1 liver,NS,carcinoma,hepatocellular carcinoma c.301+1G>C p.? 2:61522610-61522610 27
43 COSM1624082 XKR4 liver,NS,carcinoma,hepatocellular carcinoma c.1076A>G p.D359G 8:55523350-55523350 27
44 COSM1613650 XIRP2 liver,NS,carcinoma,hepatocellular carcinoma c.9350G>C p.R3117P 2:167250742-167250742 27
45 COSM3660541 XIRP1 liver,NS,carcinoma,hepatocellular carcinoma c.142C>A p.Q48K 3:39189304-39189304 27
46 COSM1625463 XIAP liver,NS,carcinoma,hepatocellular carcinoma c.493G>T p.A165S 23:123886155-123886155 27
47 COSM3663909 WWP1 liver,NS,carcinoma,hepatocellular carcinoma c.210-2A>G p.? 8:86381503-86381503 27
48 COSM1625309 WWC3 liver,NS,carcinoma,hepatocellular carcinoma c.1121C>A p.S374Y 23:10117180-10117180 27
49 COSM1621161 WTAP liver,NS,carcinoma,hepatocellular carcinoma c.283C>T p.Q95* 6:159748200-159748200 27
50 COSM6909096 WT1 liver,NS,carcinoma,hepatocellular carcinoma c.1019T>G p.L340* 11:32396283-32396283 27
Sources

Expression for Fibrolamellar Carcinoma

About this section
Search GEO for disease gene expression data for Fibrolamellar Carcinoma.
Sources

Pathways for Fibrolamellar Carcinoma

About this section

Pathways related to Fibrolamellar Carcinoma according to GeneCards Suite gene sharing:

(show all 32)
# Super pathways Score Top Affiliating Genes
1
ERK Signaling 64
Show member pathways
 13.67 FGFR1 FGFR2 ITGA1 ITGAV ITGB4 PRKACA
2
Developmental Biology 66
Show member pathways
 13.31 FGFR1 FGFR2 ITGA1 ITGAV KRT7 PRKACA
3
Phospholipase-C Pathway 64
Show member pathways
 12.87 FGFR1 FGFR2 ITGA1 ITGAV ITGB4
4
Actin Nucleation by ARP-WASP Complex 64
Show member pathways
 12.8 FGFR1 FGFR2 ITGA1 ITGAV ITGB4
5
PI3K-Akt signaling pathway 37
Show member pathways
 12.72 FGFR1 FGFR2 ITGA1 ITGAV ITGB4 PRKACA
6
Pathways in cancer 37
12.66 FGFR1 FGFR2 ITGAV PRKACA
7
Beta-Adrenergic Signaling 64
Show member pathways
 12.63 ITGA1 ITGAV ITGB4 PRKACA
8
MAPK-Erk Pathway 67
Show member pathways
 12.62 ITGA1 ITGAV ITGB4 PRKACA
9
NFAT and Cardiac Hypertrophy 64
Show member pathways
 12.58 FGFR1 FGFR2 ITGA1 ITGAV ITGB4 PRKACA
10
Regulation of actin cytoskeleton 1 37
12.39 FGFR1 FGFR2 ITGA1 ITGAV ITGB4
11
G-protein signaling RAC1 in cellular process 22
Show member pathways
 12.2 FGFR1 FGFR2 ITGA1 ITGAV ITGB4
12
Proteoglycans in cancer 37
12.13 FGFR1 ITGAV PRKACA
13
G-protein signaling Regulation of p38 and JNK signaling mediated by G-proteins 22
Show member pathways
 12.06 ITGA1 ITGAV ITGB4 PRKACA
14
Dilated cardiomyopathy (DCM) 37
Show member pathways
 12.03 ITGA1 ITGAV ITGB4 PRKACA
15
VEGF Signaling Pathway 61 67
Show member pathways
 12.03 FGFR1 FGFR2 ITGA1 ITGAV
16
ECM-receptor interaction 37
Show member pathways
 11.97 ITGA1 ITGAV ITGB4
17
Blood-Brain Barrier Pathway: Anatomy 65
Show member pathways
 11.92 ITGA1 ITGAV ITGB4
18
L1CAM interactions 66
Show member pathways
 11.86 FGFR1 ITGA1 ITGAV
19
MAPK Signaling: Mitogen Stimulation Pathway 65
Show member pathways
 11.84 FGFR1 FGFR2 ITGA1 ITGAV ITGB4
20
Reelin Pathway (Cajal-Retzius cells) 64
11.79 ITGA1 ITGAV ITGB4
21
AKT Signaling Pathway 67
11.71 FGFR1 FGFR2 ITGA1 ITGAV ITGB4
22
Angiogenesis (CST) 4
11.68 FGFR1 FGFR2 ITGAV
23
Phagocytosis of Microbes 64
11.65 ITGA1 ITGAV ITGB4
24
Neural Stem Cell Differentiation Pathways and Lineage-specific Markers 65
11.61 FGFR1 SYP VIM
25
Primary Focal Segmental Glomerulosclerosis FSGS 1
11.57 ITGAV ITGB4 VIM
26
G-protein signaling_Regulation of RAC1 activity 22
11.47 ITGA1 ITGAV ITGB4
27
Cytoskeleton remodeling_RalA regulation pathway 22
11.36 ITGA1 ITGAV ITGB4
28
Cell adhesion_Endothelial cell contacts by non-junctional mechanisms 22
11.23 ITGA1 ITGAV ITGB4
29
G-protein signaling_RhoA regulation pathway 22
11.12 FGFR1 FGFR2 ITGA1 ITGAV ITGB4 PRKACA
30
Signal transduction by L1 66
10.95 FGFR1 ITGAV
31
G-protein signaling_Rap2B regulation pathway 22
10.7 FGFR1 FGFR2 ITGA1 ITGAV ITGB4 VIM
32
G-protein signaling_Cross-talk between Ras-family GTPases 22
10.48 FGFR1 FGFR2 ITGA1 ITGAV ITGB4 PRKACA
Sources

GO Terms for Fibrolamellar Carcinoma

About this section

Cellular components related to Fibrolamellar Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 receptor complex GO:0043235 9.5 FGFR1 FGFR2 ITGB4
2 extracellular exosome GO:0070062 9.5 DNAJB1 ITGA1 ITGAV ITGB4 KRT7 PRKACA
3 focal adhesion GO:0005925 9.46 ITGA1 ITGAV ITGB4 VIM
4 excitatory synapse GO:0060076 9.26 FGFR2 SYP
5 integrin complex GO:0008305 8.8 ITGA1 ITGAV ITGB4

Biological processes related to Fibrolamellar Carcinoma according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.86 CCKBR FGFR1 FGFR2 ITGAV
2 extracellular matrix organization GO:0030198 9.75 ITGA1 ITGAV ITGB4
3 cell migration GO:0016477 9.74 FGFR1 ITGAV ITGB4
4 protein autophosphorylation GO:0046777 9.71 FGFR1 FGFR2 PRKACA
5 cell-matrix adhesion GO:0007160 9.63 ITGA1 ITGAV ITGB4
6 integrin-mediated signaling pathway GO:0007229 9.61 ITGA1 ITGAV ITGB4
7 positive regulation of mesenchymal cell proliferation GO:0002053 9.55 FGFR1 FGFR2
8 cell adhesion mediated by integrin GO:0033627 9.52 ITGAV ITGB4
9 regulation of osteoblast differentiation GO:0045667 9.51 FGFR2 PRKACA
10 mesodermal cell differentiation GO:0048333 9.49 FGFR2 ITGB4
11 branching involved in salivary gland morphogenesis GO:0060445 9.48 FGFR1 FGFR2
12 mesenchymal cell differentiation GO:0048762 9.4 FGFR1 FGFR2
13 lung-associated mesenchyme development GO:0060484 9.37 FGFR1 FGFR2
14 positive regulation of phospholipase activity GO:0010518 9.32 FGFR1 FGFR2
15 orbitofrontal cortex development GO:0021769 9.26 FGFR1 FGFR2
16 ventricular zone neuroblast division GO:0021847 9.16 FGFR1 FGFR2
17 digestive tract development GO:0048565 9.13 CCKBR FGFR2 ITGB4
18 fibroblast growth factor receptor signaling pathway involved in orbitofrontal cortex development GO:0035607 8.62 FGFR1 FGFR2

Molecular functions related to Fibrolamellar Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 insulin-like growth factor I binding GO:0031994 9.26 ITGAV ITGB4
2 fibroblast growth factor-activated receptor activity GO:0005007 9.16 FGFR1 FGFR2
3 neuregulin binding GO:0038132 8.96 ITGAV ITGB4
4 fibroblast growth factor binding GO:0017134 8.8 FGFR1 FGFR2 ITGAV
Sources

Sources for Fibrolamellar Carcinoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....